home / stock / prax / prax message board
Subject | By | Source | When |
---|---|---|---|
Despite Trial Failure Praxis Still Seeks Advancing Essential | ctb | investorshub | 03/03/2023 4:15:45 PM |
News today. | IPO$ | investorshub | 03/03/2023 4:14:25 PM |
Not looking good now. | IPO$ | investorshub | 03/03/2023 4:13:49 PM |
Getting killed this am. | IPO$ | investorshub | 03/03/2023 3:19:59 PM |
FDA phase 2 approval due in next week | IPO$ | investorshub | 03/01/2023 8:31:53 PM |
ATM offering on S-3 didnt hurt 2022 as | IPO$ | investorshub | 03/01/2023 8:31:29 PM |
Book value at 12/31/22 is $76M. Not bad. | IPO$ | investorshub | 03/01/2023 6:36:05 PM |
$61M cash at 12/31/22 with 49M shares O/S | IPO$ | investorshub | 03/01/2023 6:31:14 PM |
I wonder how much cash they have now? | IPO$ | investorshub | 03/01/2023 6:27:13 PM |
$PRAX has $5 a share cash and easily | ElCollector | investorshub | 06/15/2022 2:56:39 PM |
Looking for a gain. | rtrstock | investorshub | 03/22/2021 3:01:26 PM |
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
2024-04-26 16:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translatin...
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...